Form 8-K - Current report:
SEC Accession No. 0001104659-23-040537
Filing Date
2023-04-03
Accepted
2023-04-03 07:52:11
Documents
14
Period of Report
2023-04-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2311180d1_8k.htm   iXBRL 8-K 26556
2 EXHIBIT 99.1 tm2311180d1_ex99-1.htm EX-99.1 20508
6 GRAPHIC tm2311180d1_ex99-1img001.jpg GRAPHIC 5620
  Complete submission text file 0001104659-23-040537.txt   237578

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20230403.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20230403_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20230403_pre.xml EX-101.PRE 22599
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2311180d1_8k_htm.xml XML 3707
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 23790659
SIC: 2834 Pharmaceutical Preparations